Genelux (GNLX) Competitors

Genelux (NASDAQ:GNLX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Do analysts rate GNLX or HUMA?

Genelux presently has a consensus price target of $17.75, suggesting a potential upside of 569.81%. Humacyte has a consensus price target of $11.71, suggesting a potential upside of 386.07%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Humacyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Humacyte	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor GNLX or HUMA?

Humacyte received 27 more outperform votes than Genelux when rated by MarketBeat users. However, 94.44% of users gave Genelux an outperform vote while only 70.97% of users gave Humacyte an outperform vote.

Company	Underperform	Outperform
Genelux	Outperform Votes 17 94.44%	Underperform Votes 1 5.56%
Humacyte	Outperform Votes 44 70.97%	Underperform Votes 18 29.03%

Do insiders & institutionals believe in GNLX or HUMA?

37.3% of Genelux shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 9.3% of Genelux shares are owned by insiders. Comparatively, 5.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more risk and volatility, GNLX or HUMA?

Genelux has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.

Does the media refer more to GNLX or HUMA?

In the previous week, Humacyte had 7 more articles in the media than Genelux. MarketBeat recorded 14 mentions for Humacyte and 7 mentions for Genelux. Genelux's average media sentiment score of 0.64 beat Humacyte's score of 0.58 indicating that Genelux is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GNLX or HUMA more profitable?

Genelux's return on equity of -105.05% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-105.05%	-80.16%
Humacyte	N/A	-942.81%	-93.82%

Which has preferable valuation and earnings, GNLX or HUMA?

Genelux has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$8K	12,499.72	-$28.30M	-$0.88	-3.01
Humacyte	$517K	723.09	-$110.78M	-$0.69	-3.49

Summary

Genelux beats Humacyte on 9 of the 17 factors compared between the two stocks.